Orders flowing in as Pfizer’s COVID vaccine passes final stage
Just a week after reporting that preliminary analyses of its COVID vaccine were 90 percent effective, American pharmaceutical giant Pfizer reported this week that the vaccine has been proven to be 95 per cent effective after passing through the final testing stage.
Yesterday, Pfizer said the latest test results show its vaccine is 95 percent effective and protects older people most at risk of dying. Pfizer said the vaccine was more than 94 percent effective in people older than 65.
With the new test results, Pfizer has all it needs to seek emergency use of the vaccine from US regulators. At the same time, orders are flowing in from Canada, Australia and the UK.
Pfizer’s vaccine has been tested on 43,500 people across six countries (US, Germany, Brazil, South Africa, Turkey, and Argentina) and no safety concerns have been raised.
After announcing that its vaccine had passed the final stage, Pfizer stock market shares rose 2.7 percent in premarket trading.
Meanwhile, Pfizer’s rival Moderna on Monday released promising results for its own vaccine, adding that it, too, expects to apply for emergency authorization in the US soon.
Both the Moderna and the Pfizer-BioNTech vaccines are based on messenger RNA, a new type of vaccine technology that is able to be deployed very quickly.
It essentially transforms the body’s cells into tiny vaccine making machines. The vaccines instruct cells to make copies of the coronavirus spike protein, stimulating the production of protective antibodies.
With the new test results, Pfizer has all it needs to seek emergency use of the vaccine from US regulators. At the same time, orders are flowing in from Canada, Australia and the UK.
Pfizer’s vaccine has been tested on 43,500 people across six countries (US, Germany, Brazil, South Africa, Turkey, and Argentina) and no safety concerns have been raised.
After announcing that its vaccine had passed the final stage, Pfizer stock market shares rose 2.7 percent in premarket trading.
Meanwhile, Pfizer’s rival Moderna on Monday released promising results for its own vaccine, adding that it, too, expects to apply for emergency authorization in the US soon.
Both the Moderna and the Pfizer-BioNTech vaccines are based on messenger RNA, a new type of vaccine technology that is able to be deployed very quickly.
It essentially transforms the body’s cells into tiny vaccine making machines. The vaccines instruct cells to make copies of the coronavirus spike protein, stimulating the production of protective antibodies.
